EZH2: An Accomplice of Gastric Cancer
Gastric cancer is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Understanding the factors influencing the therapeutic effects in gastric cancer patients and the molecular mechanism behind gastric cancer is still facing challenges. In addition to genetic alterat...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/2/425 |
| _version_ | 1797444868239261696 |
|---|---|
| author | Wuhan Yu Ning Liu Xiaogang Song Lang Chen Mancai Wang Guohui Xiao Tengfei Li Zheyuan Wang Youcheng Zhang |
| author_facet | Wuhan Yu Ning Liu Xiaogang Song Lang Chen Mancai Wang Guohui Xiao Tengfei Li Zheyuan Wang Youcheng Zhang |
| author_sort | Wuhan Yu |
| collection | DOAJ |
| description | Gastric cancer is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Understanding the factors influencing the therapeutic effects in gastric cancer patients and the molecular mechanism behind gastric cancer is still facing challenges. In addition to genetic alterations and environmental factors, it has been demonstrated that epigenetic mechanisms can also induce the occurrence and progression of gastric cancer. Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressor complex 2 (PRC2), which trimethylates histone 3 at Lys-27 and regulates the expression of downstream target genes through epigenetic mechanisms. It has been found that EZH2 is overexpressed in the stomach, which promotes the progression of gastric cancer through multiple pathways. In addition, targeted inhibition of EZH2 expression can effectively delay the progression of gastric cancer and improve its resistance to chemotherapeutic agents. Given the many effects of EZH2 in gastric cancer, there are no studies to comprehensively describe this mechanism. Therefore, in this review, we first introduce EZH2 and clarify the mechanisms of abnormal expression of EZH2 in cancer. Secondly, we summarize the role of EZH2 in gastric cancer, which includes the association of the EZH2 gene with genetic susceptibility to GC, the correlation of the EZH2 gene with gastric carcinogenesis and invasive metastasis, the resistance to chemotherapeutic drugs of gastric cancer mediated by EZH2 and the high expression of EZH2 leading to poor prognosis of gastric cancer patients. Finally, we also clarify some of the current statuses of drug development regarding targeted inhibition of EZH2/PRC2 activity. |
| first_indexed | 2024-03-09T13:17:41Z |
| format | Article |
| id | doaj.art-a52266473911453fbef8ba6a827824fd |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T13:17:41Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a52266473911453fbef8ba6a827824fd2023-11-30T21:33:41ZengMDPI AGCancers2072-66942023-01-0115242510.3390/cancers15020425EZH2: An Accomplice of Gastric CancerWuhan Yu0Ning Liu1Xiaogang Song2Lang Chen3Mancai Wang4Guohui Xiao5Tengfei Li6Zheyuan Wang7Youcheng Zhang8The Second Hospital of Lanzhou University, Lanzhou 730030, ChinaThe Second Hospital of Lanzhou University, Lanzhou 730030, ChinaThe Second Hospital of Lanzhou University, Lanzhou 730030, ChinaThe Second Hospital of Lanzhou University, Lanzhou 730030, ChinaThe Second Hospital of Lanzhou University, Lanzhou 730030, ChinaThe Second Hospital of Lanzhou University, Lanzhou 730030, ChinaThe Second Hospital of Lanzhou University, Lanzhou 730030, ChinaThe Second Hospital of Lanzhou University, Lanzhou 730030, ChinaThe Second Hospital of Lanzhou University, Lanzhou 730030, ChinaGastric cancer is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Understanding the factors influencing the therapeutic effects in gastric cancer patients and the molecular mechanism behind gastric cancer is still facing challenges. In addition to genetic alterations and environmental factors, it has been demonstrated that epigenetic mechanisms can also induce the occurrence and progression of gastric cancer. Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressor complex 2 (PRC2), which trimethylates histone 3 at Lys-27 and regulates the expression of downstream target genes through epigenetic mechanisms. It has been found that EZH2 is overexpressed in the stomach, which promotes the progression of gastric cancer through multiple pathways. In addition, targeted inhibition of EZH2 expression can effectively delay the progression of gastric cancer and improve its resistance to chemotherapeutic agents. Given the many effects of EZH2 in gastric cancer, there are no studies to comprehensively describe this mechanism. Therefore, in this review, we first introduce EZH2 and clarify the mechanisms of abnormal expression of EZH2 in cancer. Secondly, we summarize the role of EZH2 in gastric cancer, which includes the association of the EZH2 gene with genetic susceptibility to GC, the correlation of the EZH2 gene with gastric carcinogenesis and invasive metastasis, the resistance to chemotherapeutic drugs of gastric cancer mediated by EZH2 and the high expression of EZH2 leading to poor prognosis of gastric cancer patients. Finally, we also clarify some of the current statuses of drug development regarding targeted inhibition of EZH2/PRC2 activity.https://www.mdpi.com/2072-6694/15/2/425gastric cancerenhancer of zeste homolog 2H3K27epigenetics |
| spellingShingle | Wuhan Yu Ning Liu Xiaogang Song Lang Chen Mancai Wang Guohui Xiao Tengfei Li Zheyuan Wang Youcheng Zhang EZH2: An Accomplice of Gastric Cancer Cancers gastric cancer enhancer of zeste homolog 2 H3K27 epigenetics |
| title | EZH2: An Accomplice of Gastric Cancer |
| title_full | EZH2: An Accomplice of Gastric Cancer |
| title_fullStr | EZH2: An Accomplice of Gastric Cancer |
| title_full_unstemmed | EZH2: An Accomplice of Gastric Cancer |
| title_short | EZH2: An Accomplice of Gastric Cancer |
| title_sort | ezh2 an accomplice of gastric cancer |
| topic | gastric cancer enhancer of zeste homolog 2 H3K27 epigenetics |
| url | https://www.mdpi.com/2072-6694/15/2/425 |
| work_keys_str_mv | AT wuhanyu ezh2anaccompliceofgastriccancer AT ningliu ezh2anaccompliceofgastriccancer AT xiaogangsong ezh2anaccompliceofgastriccancer AT langchen ezh2anaccompliceofgastriccancer AT mancaiwang ezh2anaccompliceofgastriccancer AT guohuixiao ezh2anaccompliceofgastriccancer AT tengfeili ezh2anaccompliceofgastriccancer AT zheyuanwang ezh2anaccompliceofgastriccancer AT youchengzhang ezh2anaccompliceofgastriccancer |